Avicanna Inc
🇩🇪XFRA.0NNGermanyHealthcare
Price€0.060.00 (0%)
Latest anomalies
Neutral 1 detected in the last 120 days
- High: 2
- Medium: 2
- Low: 0
52-week low: the price is trading close to this level
Effective tax rate: a sudden drop below its trailing quarter average
Leverage ratio: a sudden drop below its trailing quarter average
Current ratio: below the level we flag as a liquidity warning
Quick ratio: below the level we flag as a liquidity warning
Free with a Finzer account.
Profile
- Healthcare
- Drug Manufacturers - Specialty & Generic
- Germany
Identity
- Exchange
- Frankfurt Stock Exchange . XFRA
- Type
- Stock
- ISIN
- CA05368K1003
- CUSIP
- Not reported
Company
- Employees
- 87
- Headquarters
- Toronto, Canada
- Website
- https://www.avicanna.com
Market
- Shares outstanding
- 134.4M
- Market cap
- €8.04M
Key dates
- Next earnings
- Nov 13, 2026
Highlights
No high and low reported for today's session.
- Market cap
- €8.04M
- EPS LTM
- -CA$0.01calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- Not reported
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- CA$25.37M+2%up year on year
- Net income
- -CA$1.28M+80.44%up year on year
- Gross margin
- 53.56%+24.29%up year on year
- Free cash flow
- -CA$1.19M-99.09%down year on year
Latest news
News is not sourced for this exchange.
Business summary
Avicanna Inc is a company in the healthcare sector, listed on Frankfurt Stock Exchange (Germany) under the ticker 0NN. Its market capitalisation is €8.04M, from 134.4M shares outstanding, as of . Across the 252 trading sessions to the shares traded between €0.06 and €0.19, and the last close of €0.06 sits 0% of the way up that range. The company is headquartered in Toronto, Canada, and employs about 87 people. This is the Frankfurt Stock Exchange listing of Avicanna Inc; its primary listing is AVCN on Toronto Stock Exchange.
Avicanna Inc., a commercial-stage and international biopharmaceutical company, focuses on the development, advancement, and commercialization of evidence-based cannabinoid-based products for worldwide consumers and for medical and pharmaceutical market segments. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes advanced research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products, such as oral, sublingual, topical, and transdermal deliveries under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and feminized and standardized seeds, resins or whole plant crude oils, cannabinoid distillates, and isolated cannabinoids and bulk formulations under the Aureus brand. It also offers cannabidiol, cannabigerol, and tetrahydrocannabinol seeds under the Avesta Genetica brand name. In addition, the company is developing pharmaceutical products for epidermolysis bullosa, eczema, acne, anxiety and depression, sleep disorders, opioid addiction, epilepsy, Parkinson's disease, multiple sclerosis, chronic pain, neuropathic pain, arthritis, and palliative care diseases. Avicanna has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.